Trial record 1 of 4 for:    "Agnosia"
Previous Study | Return to List | Next Study

Orientation Agnosia: Clinical and Anatomical Study (AGNORIENT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by University Hospital, Rouen
Sponsor:
Information provided by (Responsible Party):
University Hospital, Rouen
ClinicalTrials.gov Identifier:
NCT01304576
First received: August 23, 2010
Last updated: December 21, 2012
Last verified: December 2012
  Purpose

The area of the brain responsible of visuospatial processing data and more specifically the orientation of an object or image is located in parietal lobe, especially on the right side. A dysfunction of this region would result in a disorder of recognition of the orientation of objects and images that the investigators call orientation agnosia. Several isolated cases are reported in the literature but to the investigators knowledge deficit has never been systematically searched, or put into perspective compared to other neuropsychological deficits. Moreover, the precise location of the lesion responsible for such a disorder remains uncertain. The objectives of this study are (1) detect the existence of orientation agnosia in case of right parietal lesion, and (2) to improve the understanding of such a deficit allowing better management of this disorder.


Condition Intervention
Cerebrovascular Disorders
Brain Lesions
Behavioral: Neuropsychological testing
Other: MRI

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Orientation Agnosia: Neuropsychological Evaluation, Associated Symptoms, Clinical and Anatomical Correlations

Further study details as provided by University Hospital, Rouen:

Primary Outcome Measures:
  • orientation agnosia evaluation [ Time Frame: 1 week to 6 months (average) ] [ Designated as safety issue: No ]
    orientation agnosia test


Secondary Outcome Measures:
  • associated clinical symptoms especially apraxia [ Time Frame: 1 week to 6 months (average) ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: September 2010
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: patient with right parietal lesions Behavioral: Neuropsychological testing
Experimental test about orientation agnosia and standard neuropsychological tests.
Other: MRI
Cerebral MRI
Active Comparator: patient with left parietal lesions Behavioral: Neuropsychological testing
Experimental test about orientation agnosia and standard neuropsychological tests.
Other: MRI
Cerebral MRI

Detailed Description:

Idem

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age between 18 and 80 years
  • french language
  • right parietal lesion on cerebral imaging (CT-scan is sufficient), including stroke,arterial malformation, isolated tumoral lesion
  • informed consent

Exclusion Criteria:

  • previous neurological history except non complicated migraine and stabilized epilepsia without seizure since 5 years
  • previous psychiatric history except depression without hospitalization > one week or anxiety with maximum one anxiolytic treatment
  • drug or alcohol abuse
  • severe cranial traumatism
  • other severe chronic pathology
  • psychotropic medication other than a hypnotic or an anxiolytic at low doses without dose modification for at least one month
  • visual impairment
  • motor or sensory deficit sufficient to render impossible neuropsychological tests
  • patient without judicial or administrative liberty
  • measure of legal protection or no capable to express their consent
  • pregnancy or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01304576

Contacts
Contact: Olivier MARTINAUD, Doctor 0232888740 ext +33 olivier.martinaud@chu-rouen.fr

Locations
France
CHU de Rouen - Hôpitaux de Rouen Recruiting
Rouen, Haute-Normandie, France, 76031
Contact: Olivier MARTINAUD, Doctor    0232888740 ext +33    olivier.martinaud@chu-rouen.fr   
Sub-Investigator: Aude TRIQUENOT, Doctor         
Sub-Investigator: Evelyne GUEGAN-MASSARDIER, Doctor         
Sub-Investigator: François PROUST, Professor         
Sub-Investigator: Emmanuel GERARDIN, Doctor         
Sub-Investigator: Didier HANNEQUIN, Professor         
Sponsors and Collaborators
University Hospital, Rouen
Investigators
Principal Investigator: Olivier MARTINAUD, Doctor Service de neurologie et centre mémoire de ressources et recherche
  More Information

No publications provided

Responsible Party: University Hospital, Rouen
ClinicalTrials.gov Identifier: NCT01304576     History of Changes
Other Study ID Numbers: 2009/126/HP, number ID RCB 2009-A01005-52
Study First Received: August 23, 2010
Last Updated: December 21, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by University Hospital, Rouen:
stroke
parietal lesions

Additional relevant MeSH terms:
Agnosia
Cerebrovascular Disorders
Perceptual Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Brain Diseases
Central Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 18, 2014